

**Appendix 1:** Outcomes of the randomized controlled trials included in the meta-analysis of the effectiveness of respiratory fluoroquinolones compared with other antibiotics for the treatment of community acquired pneumonia

Study	Duration of hospital stay, d, mean (SD) or median (range)	Mortality (all cause), n/N (%)	Intention-to-treat population	Treatment success; n/N (%)		
				Clinically evaluable population		
				Overall	Combination therapy	Severe community-acquired pneumonia
Carbon et al <sup>1</sup>	NA	0/348 (0) v. 2/168 (1)	286/348 (82) v. 144/168 (86)	275/291 (95) v. 141/148 (95)	NA	NA
D'Ignazio et al <sup>2</sup>	NA	2/212 (1) v. 1/211 (0.5)	189/212 (89) v. 180/211 (85)	177/189 (94) v. 156/174 (90)	NA	NA
Erard et al <sup>3</sup>	median 8 (2-74) v. 10 (3-29)	1/79 (1) v. 3/37 (8)	NA	72/79 (91) v. 34/37 (92)	72/79 (91) v. 18/20 (90)	28/28 (100) v. 14/14 (100)
File et al <sup>4</sup>	NA	1/291 (0.3) v. 5/293 (2)	NA	217/226 (96) v. 208/230 (90)	NA	NA
Finch et al <sup>5</sup>	mean (SD) 9.5 ± 7.3 v. 10.4 ± 7.5	9/301 (3) v. 17/321 (5)	NA	241/258 (93) v. 239/280 (85)	241/258 (93) v. 144/168 (86)	NA
Fogarty et al <sup>6</sup>	NA	15/132 (11) v. 9/137 (7)	96/132 (73) v. 88/137 (64)	85/95 (90) v. 74/89 (83)	85/95 (90) v. 74/89 (83)	16/19 (84) v. 12/19 (63)
Fogarty et al <sup>7</sup>	NA	NA	219/235 (93) v. 221/238 (93)	184/194 (95) v. 178/188 (95)	NA	NA
Frank et al <sup>8</sup>	NA	2/113 (2) v. 4/118 (3)	95/106 (90) v. 90/105 (86)	80/85 (94) v. 72/78 (92)	NA	NA
Geijo Martinez et al <sup>9</sup>	mean 10.9 v.13.8	1/20 (5) v. 1/29 (3)	NA	19/20 (95) v. 26/29(90)	NA	NA
Gotfried et al <sup>10</sup>	NA	NA	NA	107/124 (86) v. 113/128 (88)	NA	NA
Hoeffken et al <sup>11</sup>	NA	7/453 (2) v. 5/222 (2)	NA	336/357 (94) v. 164/174 (94)	NA	NA
Kalbermatter et al <sup>12</sup>	NA	NA	NA	27/28 (96) v. 52/56 (93)	NA	NA
Katz et al <sup>13</sup>	NA	10/167 (6) v. 7/168 (4)	93/111 (84) v. 93/116 (80)	90/108 (83) v. 90/113 (80)	90/108 (83) v. 58/75 (77)	20/27 (74) v. 18/26 (69)
Leophonte et al <sup>14</sup>	NA	4/167 (2) v. 3/153 (2)	143/167 (86) v. 128/153 (84)	122/128 (95) v. 109/121 (90)	NA	26/26 (100) v. 23/26 (88)
Lin et al <sup>15</sup>	mean 7.4 ± 3.1 v. 6.8 ± 2.1	NA	18/26 (69) v. 17/24 (71)	18/23 (78) v. 17/22 (77)	18/23 (78) v. 17/22 (77)	NA
Lode et al <sup>16</sup>	median 8 (1-32) v. 9 (1-45)	3/169 (2) v. 6/172 (3)	NA	118/123 (96) v. 124/129 (96)	NA	20/23 (87) v. 20/24 (83)
Norrby et al <sup>17</sup>	median 11 v. 13	21/314 (7) v. 22/305 (7)	239/314 (76) v. 229/305 (75)	105/127 (83) v. 113/139 (81)	NA	NA
Petitpretz et al <sup>18</sup>	NA	3/200 (2) v. 4/208 (2)	173/200 (87) v. 171/208 (82)	162/177 (92) v. 166/185 (90)	NA	NA
Portier et al <sup>19</sup>	NA	6/171 (4) v. 7/175 (4)	142/171 (83) v. 136/175 (78)	131/151 (87) v. 120/138 (87)	NA	NA
Torres et al <sup>20</sup>	median 7 (2-49) v. 7 (2-30)	4/274 (2) v. 5/279 (2)	218/233 (94) v. 229/244 (94)	201/215 (94) v. 217/231 (94)	201/215 (94) v. 134/143 (94)	41/45 (91) v. 31/37 (84)
Welte et al <sup>21</sup>	median 9 v. 11	6/200 (3) v. 7/197 (4)	150/200 (75) v. 140/197 (71)	138/161 (86) v. 135/156 (87)	NA	21/27 (78) v. 19/27 (70)
Xu et al <sup>22</sup>	NA	NA	18/20 (90) v. 19/20 (95)	18/20 (90) v. 19/20 (95)	18/20 (90) v. 19/20 (95)	NA
Zervos et al <sup>23</sup>	mean 8.4 ± 6.9 v. 7.7 ± 4.7	5/102 (5) v. 3/110 (3)	83/93 (89) v. 85/97 (88)	67/75 (89) v. 75/82 (92)	NA	NA

Note: NA = not available

## References:

1. Carbon C, Ariza H, Rabie WJ, et al. Comparative study of levofloxacin and amoxicillin/clavulanic acid in adults with mild-to-moderate community-acquired pneumonia. *Clin Microbiol Infect* 1999;5:724-32.
2. D'Ignazio J, Camere MA, Lewis DE, et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. *Antimicrob Agents Chemother* 2005;49:4035-41.
3. Erard V, Lamy O, Bochud PY, et al. Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia. *Eur J Clin Microbiol Infect Dis* 2004;23:82-8.
4. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. *Antimicrob Agents Chemother* 1997;41:1965-72.
5. Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. *Antimicrob Agents Chemother* 2002;46:1746-54.
6. Fogarty C, Siami G, Kohler R, et al. Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults. *Clin Infect Dis* 2004;38(Suppl 1):S16-23.
7. Fogarty C, Grossman C, Williams J, et al. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. *Infect Med* 1999;16:748-63.
8. Frank E, Liu J, Kinasewitz G, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. *Clin Ther* 2002;24:1292-308.
9. Geijo Martinez MP, Diaz de Tuesta Chow-Quan AM, Herranz CR, et al. Levofloxacin versus beta-lactamic therapy in community acquired pneumonia that requires hospitalization. *Med Interna* 2002;19:621-5.
10. Gotfried MH, Dattani D, Riffer E, et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. *Clin Ther* 2002;24:736-51.
11. Hoeffken G, Meyer HP, Winter J, et al.; Community-acquired Pneumonia Study Group. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. *Respir Med* 2001;95:553-64.
12. Kalbermatter V, Bagilet D, Diab M, et al. Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization. *Med Clin (Barc)* 2000;115:561-3.
13. Katz E, Larsen LS, Fogarty CM, et al. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. *J Emerg Med* 2004;27:395-405.
14. Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. *Respir Med* 2004;98:708-20.
15. Lin TY, Lin SM, Chen HC, et al. An open label randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia. *Chang Gung Med J* 2007;30:321-32.
16. Lode H, File TM Jr, Mandell L, et al.; 185 Gemifloxacin Study Group. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. *Clin Ther* 2002;24:1915-36.
17. Norrby SR, Petermann W, Willcox PA, et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. *Scand J Infect Dis* 1998;30:397-404.
18. Petitpretz P, Arvis P, Marel M, et al.; CAP5 Moxifloxacin Study Group. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. *Chest* 2001;119:185-95.

Appendix to: Vardakas KZ, Siempos II, Grammatikos A, et al. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. *CMAJ* 2008;179:1269-77. Copyright © 2008, Canadian Medical Association.

19. Portier H, Brambilla C, Garre M, et al. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors. *Eur J Clin Microbiol Infect Dis* 2005;24:367-76.
20. Torres A, Muir JF, Corris P, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. *Eur Respir J* 2003;21:135-43.
21. Welte T, Petermann W, Schurmann D, et al.; MOXIRAPID Study Group. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. *Clin Infect Dis* 2005;41:1697-705.
22. Xu S, Xiong S, Xu Y, et al. Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia. *J Huazhong Univ Sci Technol Med Sci* 2006;26:421-4.
23. Zervos M, Mandell LA, Vrooman PS, et al. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. *Treat Respir Med* 2004;3:329-36.